Phase 1, first-in-human trial to evaluate the safety, tolerability, and pharmacokinetics of ascending single oral doses of octreotide/ LipOra peptide in healthy volunteers
Phase 1
Completed
- Conditions
- Acromegalia
- Registration Number
- 2024-514225-30-00
- Lead Sponsor
- Universitaetsklinikum Heidelberg AöR
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ended
- Sex
- Not specified
- Target Recruitment
- 45
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Not specified
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie octreotide/LipOra peptide's action in acromegaly treatment?
How does octreotide/LipOra compare to somatostatin analogs in acromegaly management?
What biomarkers are associated with octreotide/LipOra response in acromegalic patients?
What adverse events are reported in first-in-human trials of octreotide/LipOra formulations?
What are the current combination therapies being explored for acromegaly alongside somatostatin analogs?
Trial Locations
- Locations (1)
Universitaetsklinikum Heidelberg AöR
🇩🇪Heidelberg, Germany
Universitaetsklinikum Heidelberg AöR🇩🇪Heidelberg, GermanyAntje BlankSite contact+4962215638745Antje.Blank@med.uni-heidelberg.de